Data from Phase 3b ENSURE-AF Study Investigating Once-Daily LIXIANA® (edoxaban)in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016

Munich (ots/PRNewswire) -

- ENSURE-AF results to be featured during a late-breaking clinical
trial session
- Five abstracts highlighting analyses from the global phase 3
ENGAGE AF-TIMI 48 study to be presented
- Seven abstracts to reveal new findings from the PREFER in AF and
VTE European patient registries

Daiichi Sankyo Europe GmbH Group (hereafter, Daiichi Sankyo) today
announced the presentation of 13 abstracts at the ESC Congress 2016,
taking place from August 27-31 in Rome, Italy. The first results from
ENSURE-AF, the largest prospective randomized clinical trial to date
evaluating a non-vitamin K antagonist oral anticoagulant (NOAC)
compared to a current standard of care in patients with non-valvular
atrial fibrillation (NVAF) undergoing electrical cardioversion, which
included nearly 2,200 patients from 19 countries, will be featured in
a late-breaking clinical trial presentation. In addition, five
analyses from the global phase 3 ENGAGE AF-TIMI 48 study of edoxaban
(known by the brand name LIXIANA® outside the US and SAVAYSA® in the
US) will be presented, including clinical outcomes associated with
dose interruption in patients with NVAF compared to warfarin,
relationship between body mass index and clinical outcomes, and a
novel risk prediction score for net clinical outcome assessment.

Furthermore, six analyses from the PREFER in atrial fibrillation
(AF) registry and one analysis from the PREFER in venous
thromboembolism (VTE) registry will be presented, with new insights
into the use of NOAC therapy, including prescribing patterns and
trends in acute and long-term management of patients with AF and VTE.

Details of the presentations are included below:



Presentation Title Presenter
Session Details


Late-breaking Oral Presentation

Edoxaban for Cardioversion of Andreas Goette, MD,
Tuesday, August 30,
Atrial Fibrillation: The Edoxaban St.
Vincenz-Hospital, 2:00-2:15 PM CET
Versus Warfarin in
Subjects Paderborn, Germany Location: Rome -

Undergoing Cardioversion of
Main Auditorium
Atrial Fibrillation (ENSURE-AF)
Study


Poster Presentations
Evolution of
Symptoms, Rate, and Yanish Purmah, MD, Sunday, August
28,
Rhythm Control Therapy in AF City Hospital,
8:30 AM-12:30 PM CET
Patients in Europe: A Comparison
Birmingham, United Location:
of the PREFER in AF and
PREFER in Kingdom Poster Area
AF
Prolongation Data Sets



Insulin-requiring Versus Elisabetta Ricottini,
Sunday, August 28,
Non-insulin Requiring Diabetes MD,
University Campus 2:00-6:00 PM CET